Biodexa Pharmaceuticals (BDRX) Assets (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Assets of $24.2 million for Q4 2025, up 22.28% sequentially from $19.8 million in Q2 2025, and up 27.47% YoY from $19.0 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Assets (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Assets for 13 years, with the latest figure at $24.2 million in Q4 2025.
- Quarterly Assets rose 27.47% year-over-year to $24.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.2 million (up 27.47% YoY) and the FY2025 annual result came in at $24.0 million, up 26.35% from the prior year.
- Assets improved to $24.2 million in Q4 2025 per BDRX's latest filing, from $19.8 million in the prior quarter.
- Over five years, Assets peaked at $24.2 million in Q4 2025 and troughed at $6.5 million in Q4 2022.
- A 5-year average of $15.1 million and a median of $15.2 million in 2021 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets slumped 62.77% in 2022, then soared 101.9% in 2023.
- Over 5 years, Assets stood at $17.4 million in 2021, then plunged by 62.77% to $6.5 million in 2022, then soared by 101.9% to $13.1 million in 2023, then soared by 44.98% to $19.0 million in 2024, then climbed by 27.47% to $24.2 million in 2025.
- According to Business Quant data, Assets over the past three periods registered $24.2 million, $19.8 million, and $19.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 24.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.18 Mn |
| Jun 30, 2025 | 19.78 Mn |
| Dec 31, 2024 | 18.97 Mn |
| Jun 30, 2024 | 17.63 Mn |
| Dec 31, 2023 | 13.08 Mn |
| Jun 30, 2023 | 9.96 Mn |
| Dec 31, 2022 | 6.48 Mn |
| Jun 30, 2022 | 12.19 Mn |
| Dec 31, 2021 | 17.41 Mn |
| Jun 30, 2021 | 11.57 Mn |
| Dec 31, 2020 | 12.96 Mn |
| Jun 30, 2020 | 14.90 Mn |
| Dec 31, 2019 | 39.72 Mn |
| Jun 30, 2019 | 36.70 Mn |
| Dec 31, 2018 | 26.31 Mn |
| Jun 30, 2018 | 48.84 Mn |
| Dec 31, 2017 | 65.35 Mn |
| Jun 30, 2017 | 57.86 Mn |
| Dec 31, 2016 | 70.48 Mn |
| Jun 30, 2016 | 81.30 Mn |